Kevin Du, M.D., PhD, MSCI
Dr. Kevin Du joined Yale Cancer Center and Smilow Cancer Hospital from NYU Langone Health in NYC, where he was an Associate Professor of Radiation Oncology and Director of the Residency Program in Radiation Oncology. He received his medical degree from the University of Pennsylvania School of Medicine in 2006, where he also received his PhD in Cellular and Molecular Biology in 2003. He received a master’s degree in Clinical Investigation from the New York University School of Medicine and has led numerous clinical trials at NYU.
Cathy Eng, M.D., FACP, FASCO
Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program. She joined the faculty at Vanderbilt-Ingram Cancer Center in July 2019.
Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers. She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers. She has published multiple publications on these GI malignancies.
Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force. She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee. She is a member of the Anal Cancer Foundation Scientific Advisory Board.
William Goeren, L.C.S.W-R, SEP, A.C.S.W.
William Goeren, LCSW-R, SEP, ACSW currently runs his own private practice in NYC. Previously, he was the Director of Clinical Programs for CancerCare. Prior to this work at CancerCare, Bill was the Director of Mental Health for the AIDS HealthCare Foundation in Los Angeles. Bill is the co-author of the chapter “Unique Issues Confronting Gay, Lesbian, and Bisexual Individuals Diagnosed with Cancer” for the Oxford University Press “Handbook of Oncology Social Work” and the author of the chapter “Social Work, HIV Disease, and Palliative Care” for the “Oxford Textbook of Palliative Social Work”. His specialties include somatic trauma psychotherapy, applicable to both chronic and acute trauma.
Emma Holliday, M.d.
Emma Holliday is an associate professor of gastrointestinal radiation oncology at The University of Texas MD Anderson Cancer Center. She has clinical and research focus in the treatment of patients with anal squamous cell carcinoma.
She is interested in expanding methods for reducing radiation toxicities and improving quality of life for patients in survivorship.
Michael C. LaSala, Ph.D., LCSW
Michael C. LaSala, PhD, LCSW is a professor at Rutgers University and has practiced psychotherapy for over 35 years. He is also an openly gay man. Professor LaSala’s first book entitled: Coming Out, Coming Home (Columbia University Press) describes the findings and family therapy implications of a study of 65 gay and lesbian youth and their families. He is also the author of the newly released: Clinical Social Work with Individuals, Families, and Groups: The Power of Healing Relationships (Routledge) which is a textbook for new psychotherapists. Identifying and accessing his own and his client strengths is a lifelong commitment of Dr. LaSala, and is what helped him get through his anal cancer experience. He uses these skills to assist others in his role as a mentor for the HPV and Anal Cancer Foundation.
Joel Palefsky, M.D., C.M., F.R.C.P.(C).
Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the founder and director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study that showed that treatment of anal cancer precursor lesions prevents the development of anal cancer. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society.He is the founder and chairperson of the IPVS International HPV Awareness Day Campaign and is a member of the scientific advisory board of the Anal Cancer Foundation.
Paul Romesser, MD
Dr. Romesser is the Director of Colorectal Anal Cancer in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center, and Member of Early Drug Development Service in the Department of Medicine. He is a physician scientist with an interest in developing novel radiation sensitizers for colorectal anal cancers. He is a member of the NRG Oncology colorectal and non-colorectal committees and the NCI Colon Task Force. His work has been published in the New England Journal of Medicine, Nature, Science, Cell, Journal of Clinical Oncology, Lancet Oncology, Clinical Cancer Research, International Journal of Radiation Oncology and Biophysics, and Cancer. Dr. Romesser is also a member of the Scientific Advisory Board of the Anal Cancer Foundation.